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Reducing duplex examinations in patients with
iatrogenic pseudoaneurysms
Patrick A. Stone, MD, Ali F. AbuRahma, MD, and Sarah K. Flaherty, BS, Charleston, Va
Objective: Ultrasound-guided thrombin injection has become the initial treatment of choice for femoral access-related
pseudoaneurysms. Patients typically undergo serial duplex examinations to assess for spontaneous resolution of small
iatrogenic pseudoaneurysms (IPSAs) (<2.5 cm), or may require repeated diagnostic, therapeutic, and follow-up studies
for larger IPSAs (>2.5 cm). We evaluated the impact of a revised treatment algorithm that includes primary treatment of
both small (<2.5 cm) and larger pseudoaneurysms (>2.5 cm), rather than observation of smaller ones, and attempts to
establish a single duplex examination via a point-of-care treatment strategy.
Methods: We reviewed 105 consecutive patients treated with ultrasound-guided thrombin injection from July 2001
through September 2004. Patient, IPSAs, characteristics, and treatment methods were examined. The number of duplex
examinations per patient was evaluated over the treatment interval. Also, published cost data were used to compare
primary treatment of small ISPAs vs observation with serial duplex examinations.
Results: Successful thrombosis occurred in 103 (98.1%) of 105 treated pseudoaneurysms. No minor or major complica-
tions occurred after thrombin injection in either small or large ISPAs, and both failures requiring operation were in the
large aneurysm group. The recurrence rate for the series was 1.9% (2/105), and both recurrences were successfully treated
with an additional thrombin injection. A single injection was successful in treating 43 (97.7%) of 44 small (<2.5 cm)
IPSAs, and one required a second injection. Patients had an average of 3.3 duplex examinations in our first year of
treatment experience, which declined to 1.5 by our third year with the institution of a point-of-care service model for all
pseudoaneurysms. Based on this decreased use of duplex examination and an average treatment cohort of 35 IPSA
patients per year our institution, we determined this results in a reduction of 35 hours of laboratory time and nearly 70
ultrasounds per year. Similarly for small pseudoaneurysms, a point-of-service primary treatment program rather than
observation results in an estimated cost savings of $12,000, based on treating 15 small IPSAs per year.
Conclusions: Ultrasound-guided thrombin injection is safe and effective for the treatment of nearly all iatrogenic
pseudoaneurysms. We recommend primary treatment of small pseudoaneurysms by ultrasound-guided thrombin
injection rather than observation with serial duplex scans. A point-of-care treatment algorithm can result in cost savings
by reducing the number of necessary duplex examinations. ( J Vasc Surg 2006;43:1211-5.)Iatrogenic femoral pseudoaneurysms (IPSAs) occur in-
frequently after arterial cannulation procedures, but they
are a significant complication in that they are associated
with longer hospital stays, patient discomfort, and histori-
cally, a considerable risk of operative repair and its associ-
ated morbidity. However, as nonoperative means of false
aneurysmmanagement (observation, compression therapy,
duplex-guided thrombin injection) have increased, the
need for operative repair has been reduced.
Additionally, after multiple retrospective studies as well
as a recent prospective randomized trial by Lonn et al,1
most centers have abandoned the use of ultrasound-guided
compression therapy in favor of duplex-guided thrombin
injection (DGTI). However, uncertainty remains concern-
ing the amount of follow-up required for all IPSA as well as
the appropriate management of small (2.5 cm) IPSAs.
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doi:10.1016/j.jvs.2006.02.044In an era cost containment, we have used our experi-
ence and the available literature to construct a cost-effective
treatment algorithm for the management of IPSAs. This
algorithm includes the primary treatment of small (1 to
2.5 cm) IPSAs, a point-of-care service model, and limits
follow-up duplex examinations.
PATIENTS AND METHODS
From July 1, 2001 to September 1, 2004, approxi-
mately 30,000 catheterization procedures were performed
at Charleston Area Medical Center in Charleston, WV.
During that same time period, 105 patients were treated for
femoral IPSAs with DGTI. Exclusion criteria included
known thrombin allergy, hemodynamic instability (those
with expanding pulsatile hematomas with associated hypo-
tension, which were felt to have active bleeding), apparent
infected IPSAs, and anastomotic pseudoaneurysms. After
Institutional Review Board approval, a retrospective review
was performed of 105 patients’ charts.
Diagnostic arterial duplex examinations were per-
formed using a Philips HDL 5000 ultrasound machine
(Philips Medical Systems, Andover, Mass) with a 5-MHz
to 7-MHz linear array transducer. The groin was pre-
pared with povidone-iodine (Betadine, Purdue Pharma
LP, Stamford, Conn), and a local anesthetic (lidocaine 1%)
was administered. A spinal needle (20 or 22 gauge) and
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(1,000 IU/mL) in 0.1-mL increments, which was injected
into the sac of the pseudoaneurysmwith ultrasound guidance.
Color duplex ultrasonography was used to assess thrombosis
during and immediately postprocedure. Patients were kept at
bed rest for 4 to 6 hours postprocedure.
Approximately 2 years into the study period, the treat-
ment algorithm for IPSA at our institution was changed.
Initially, treatment included a diagnostic duplex examina-
tion, a therapeutic exam, and a routine follow-up examina-
tion at 24 hours postprocedure. During our second year of
experience, we attempted to adopt a treatment strategy that
condensed the diagnostic and treatment sessions into the
same exam, and then a follow-up examination. After re-
viewing our results during the third year of the study
period, we implemented a point-of-care model that in-
volved a single diagnostic/treatment examination only,
with a clinical examination performed in all patients 1
week of hospital discharge.
Patient demographics, pseudoaneurysm anatomy, pro-
cedural details, outcomes, and complications were docu-
mented and analyzed. Post-successful injection follow-up
ultrasound scans were evaluated and deemed to be of
clinical significance if the pseudoaneurysm had recurred.
RESULTS
We analyzed 105 patients (34 men, 71 women) with
IPSA. Their average age was 67 years, and their average
body surface area was 1.95 m2. Seventy-one percent were
taking at least one preoperative antiplatelet or anticoagu-
lant (aspirin, clopidogrel, warfarin, or eptifibatide) medica-
tion. Catheterization was performed with an average sheath
size of 7F (range, 5F to 9F), and closure devices were used
in 3.8% (n  4). Closure device use in the catheterization
population as a whole during the study period was approx-
imately 22%. The mean IPSA size was 3.1 cm (range, 1.0 to
8.2 cm), with an average neck width of 0.35 cm (only 42%
had a recorded neck size). One quarter of the patients
(25.6%) were treated for complex IPSAs, which generally
consisted of multiple small sacs.
IPSAs were successfully treated with DGTI in 103
(98.1%) of 105 patients. Two patients (1.9%) ultimately
required an operative repair secondary to failed DGTI. One
had a stellate arterial laceration, and the other had a chronic
pseudoaneurysm that was surgically excised. Two patients
who had had initial successful DGTI had recurrences, for an
overall recurrence rate of 1.9% (2/105). Both recurrences
were diagnosed at the 1-week clinical follow-up visit, and
both were successfully treated with an additional DGTI.
One recurrence was a large IPSA (4.3 cm), which was
probably incompletely thrombosed during the initial treat-
ment, secondary to the patient’s morbid obesity. The other
recurrence was a small IPSA (1.9 cm) in an elderly woman.
A daily aspirin regimen had been prescribed for both pa-
tients who had recurrences. A single injection was success-
ful in treating 43 (97.5%) of 44 small (2.5 cm) IPSAs, and
one required a second injection. No thromboembolic, al-
lergic, or infectious complications of DGTI were noted inthis series. No minor or major complications occurred after
thrombin injection, and both failures requiring operation
were in patients with large IPSAs (5 cm).
Follow-up duplex was performed 1 week on 71
(67.6%) of 105 cases, whereas the remainder received only
clinical follow-up at the surgeon’s discretion. Patients had
an average of 3.3 duplex exams in our first year of treatment
experience, which had declined to 1.5 by our third year
after the institution of a point-of-care service model for all
pseudoaneurysms (Table I).
All of these were inpatients and, therefore, all studies
were lumped under diagnosis-related groups and not reim-
bursed per examination, as would be the case in an outpa-
tient setting. However, a limited cost evaluation was con-
ducted based on a hospital resource usage, specifically,
laboratory time and number of ultrasounds per patient. We
estimated that each exam used approximately 30minutes of
laboratory time. Charges such as surgeon’s services and
other hospitalization charges were not considered.
Following a traditional IPSA management protocol,
each patient would receive at least three duplex exams and
use an average of 1.5 hours of laboratory time (Fig). Under
a point-of-service model, patients would only have a single
ultrasound examination and only 30 minutes of laboratory
time would be used. Given that our institution treats an
average of 35 IPSAs per year, moving to a point-of-care
service algorithm would represent a reduction of 35 hours
of laboratory time and nearly 70 ultrasound examinations
per year. Such reductions represent a substantial cost sav-
ings.
Similarly, if aggressive treatment for small pseudoaneu-
rysms is included in the point-of-service primary treatment
program vs observation, additional savings on patient
charges may be realized. An observation model generally
calls for one inpatient ultrasound scan and two outpatient
ultrasound scans, with each outpatient ultrasound scan
costing approximately $400. We can estimate that our
institution treats 15 small IPSAs per year (40% of all IPSAs),
which would equate with an estimated cost savings of
$12,000. As the recurrence rate for most IPSA is generally
around 3%, the additional charges to treat patients who
have a recurrence would be negligible compared with the
Table I. Summary by year
Year 1 Year 2 Year 3
IPSAs treated (n) 50 32 23
Small IPSA treated (n)* 22 14 8
Exams per patient (mean) 3.3 2.6 1.5
DGTI success (%) 96 100 100
Recurrence (%) 4 0 0
IPSA, Iatrogenic pseudoaneurysms; DGTI, duplex-guided thrombin injec-
tion.
*2.5 cm.savings achieved.
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Although technologic advances have provided small-
er-profile interventional equipment, a decrease in the
number of postprocedural arterial site complications has
likely been limited by the judicious use of newer antico-
agulant medications. Devices to close arterial punctures
should similarly led to a decrease the frequency of arterial
complications, but a recent meta-analysis by Koreny et
al2 failed to show this. In fact, these devices may actually
increase the frequency of pseudoaneurysms as well as
pose additional risks.
When symptomatic IPSA are identified after percutane-
ous arterial procedures, management options at most insti-
tutions vary and include observation, duplex-guided throm-
bin injection, and surgical repair. Management strategy is
generally determined by symptomatic status and the maxi-
mum sac diameter of the IPSA (assuming hemodynamic
stability). Most vascular surgeons agree with treatment of
symptomatic IPSAs with a maximum sac diameter 2.5
cm; however, some authors have advocated for only obser-
vation of small (3.0 cm) pseudoaneurysms.
Khoury et al3 recommend surveillance of IPSAs 2.5
cm after experiencing two intra-arterial injections in 54
patients (3.7%), whereas Toursarkissian et al4 recom-
mended observation at 3 cm, as only 12% of IPSAs
required eventual therapy and no adverse patient outcomes
occurred while they were under observation. Some caveats
of this study must be examined, however. First, several
contraindications prohibited observation, which included
pain, extensive hematoma, patient preference or inability to
comply with follow up, and need for long-term anticoagu-
lation. Second, specific contraindications to newer anti-
platelet medications, including clopidogrel, were not re-
Treatment Algorithms
Clinical Follow-up
Follow-up Ultrasound
0.5 hrs
Treatment Ultrasound
0.5 hrs
Diagnostic Ultrasound
0.5 hrs
Traditional Management
1.5 hrs per patient
Clinical Follow-up
Diagnostic/Treatment Ultrasound
0.5 hrs
Point of Service Management
0.5 hrs per patient
IPSA
Fig 1. Treatment algorithms for iatrogenic pseudoaneurysms
(IPSA).ported. In general, the success of observation in patientswho are taking modern antiplatelet medications was not
evaluated.
Although our institution is a tertiary care center, it
treats patients who predominately reside in rural areas.
Compliance is a concern for most practitioners and leads to
treatment of small symptomatic IPSAs. In this experience,
44 patients with small IPSA were successfully treated: only
one required a second injection, and no intra-arterial injec-
tions were necessary. Additionally, given such success, we
see no reason why a similar treatment algorithm would be
inappropriate in urban centers where patient follow-up can
also be difficult, albeit for different reasons.
In addition to primary treatment of small IPSAs, we
have adopted a treatment strategy in our vascular labora-
tory that includes point-of-service care, when possible
(Fig). This is achieved by notifying the admitting attending
at the time of diagnosis of a femoral false aneurysm in the
noninvasive laboratory and a subsequent consultation with
a vascular surgeon at that time. In this way, most of the time
we can provide thrombin injection treatment at the time of
diagnosis and prevent an additional duplex study (ie, the
patient only gets a diagnostic examination). This is particularly
feasible in academic institutions such as ours, where senior
surgical residents are proficient at performing ultrasound-
directed procedures after showing competency with a mini-
mum of five procedures performed under the direction of
experienced attending staff. However, small or complex
IPSAs may be best treated by experienced attendings to
maximize patient safety.
This treatment algorithm is not always implemented to
perfection, but the number of duplex exams per patient did
steadily decrease to 1.5, a substantial improvement com-
pared the 3.3 examinations per patient during our first
treatment year. The main handicap to achieving one exam-
ination per patient is that there are always some instances
when a surgeon is not available; thus, a second duplex study
will be required for treatment.
An essential part of reducing duplex examinations and
the point-of-care treatment model is that once successful
thrombosis of an IPSA has been documented, we do not
routinely perform follow-up examinations to confirm per-
sistent sac thrombosis. We have previously reported our
stance on follow-up examinations after successful duplex-
guided thrombin injection, in which we found a 3% risk
of recurrence after successful thrombosis of the false aneu-
rysm in a series of 82 IPSAs.5 Additionally, both patients
with recurrent IPSAs were clinically symptomatic; hence,
we determined that follow-up examinations could be per-
formed by a physical examination, with follow-up duplex
scans reserved for those with persistent or recurrent symp-
toms.
The durability of thrombin injection in the treatment
of IPSAs has been generally well documented. A thorough
literature review showed an overall recurrence rate of about
3% (Table II). In particular, Calton et al15 followed 32
patients for an average of 9 months with serial duplex
ultrasound scans and found no recurrences or late compli-
cations. This stance has several limitations, however.We are
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not having clinically relevant recurrences, but without a
follow-up duplex examination, this cannot be verified. Ad-
ditionally, certain subsets of patients will require additional
duplex studies, such as those who extremely obese and
those with residual groin hematoma in whom clinical phys-
ical follow-up is inadequate. Our final year of experience
reflects this in that we were only able to achieve an average
of 1.5 exams per person.
Additionally, as stated by Sheiman et al,29 as well as in
our own experience, there are no good predictors of which
patients will have recurrences, so it cannot be stated with
total certainty in which patient the follow-up examinations
can be completely eliminated. Recurrences in most series
are reported to be about 2% to 3%, but some isolated
centers have reported higher rates of recurrence, up to
16%.28 A large prospective study to determine who is at
highest risk of recurrence would be helpful in addressing
this issue.
Nonetheless, the potential benefits of point-of-service
therapy are obvious. Concerns with patient follow-up com-
pliance are eliminated, and the cost savings is substantial.
Not including the costs of extra hospital days that are used
by inefficient care, the discomfort to which the patient is
Table II. Literature review of pseudoaneurysm
recurrences
Author
Successful
DGTI (n) Recurrence at follow-up
Liau et al6 5 0 (24 hours)
Kang et al7 20 0 (1-4 days)
Lennox et al8 30 0 (24 hours & 3 weeks)
Brophy et al9 15 0 (1 week)
Sackett et al10 29 0 (24 hours)
Pezzullo et al11 23 1 (24 hours)
Paulsen et al12 23 0 (24 hours)
Tamim et al13 10 0 (1 & 3 weeks)
La Perna et al14 66 3 (24 hours)
Calton et al15 52 2 (24 hours)
Sheiman et al16 50 0 (10 days)
Olsen et al 17 33 1 (24 hours)/1 (1 week)
Friedman et al18 40 0 (24 hours)/1 (1 week)
Lonn et al1 33 2 (1 week)
Khoury et al3 126 9 (1-30 days)
Chattar-Cora et al19 39 0 (24 hours)
Demharter et al20 54 1 (24 hours)
Krueger et al21 240 6 (24 hours)/4 (1 week)
Maleux et al22 57 2 (1 week)
Paulson et al23 110 0 (24 hours)
Mohler et al24 89 2 (24 hours)
Edgerton et al25 45 4 (1-30 days)
Weinmann et al26 33 1 (24 hours) brachial artery
Kang et al27 20 0 (1-4 days)
Corso et al28 30 5 (24 hours & 1/3 months)
Stone et al (current
series) 103 2 (1 week)
Total 1375 47*
DGTI, duplex-guided thrombin injection.
*Overall recurrence rate of 3.4%.subjected and costs of repeat examinations are unnecessary.CONCLUSION
Duplex-guided thrombin injection should be the initial
treatment for postcatheterization false aneurysms. Treat-
ment of small pseudoaneurysms is safe and more cost-
effective than observation. Attempts at point-of-service
care can limit unnecessary examinations and patient time.
Limiting postprocedural follow-up duplex examinations
appears to be safe and can be considered in most patients.
However, given the absence of failure predictors and the
variable recurrence rate, those with recurrent symptoms or
concerns upon physical examination should prompt addi-
tional duplex examinations.
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